Century Therapeutics(IPSC) - 2025 Q1 - Quarterly Results

Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value Enhanced · Four potentially transformative Preclinical · Leading programs focus on iPSC- programs engineered with industry- derived 'tunable' CD4+/CD8+ aß T cells Pipeline leading Allo-Evasion™ 5.0 Selective expansion to non-immune . Century effector cells in high impact diseases Therapeutics: Concentrating clinical focus with CNTY-101 on autoimmune disorders with transformational Clear focus on potential Concentrate ...